Status:
COMPLETED
Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine
Lead Sponsor:
Neurology Group of Bergen County, P.A.
Collaborating Sponsors:
Shire
Conditions:
Attention-deficit/Hyperactivity Disorder
Eligibility:
All Genders
6-12 years
Phase:
PHASE4
Brief Summary
This study is investigating the effect of sustained-release guanfacine (Intuniv) on language-based learning skills in children age 6-12 who are diagnosed with attention deficit hyperactivity disorder ...
Detailed Description
LANGUAGE-BASED LEARNING SKILLS AND ADHD: IMPACT OF TREATMENT WITH SUSTAINED-RELEASE GUANFACINE Background: Children with attention-deficit/hyperactivity disorder (ADHD) often do poorly in school (1,...
Eligibility Criteria
Inclusion
- Diagnosis of ADHD-inattentive or combined type.
Exclusion
- Intelligence (IQ) below 85 as determined by formal testing.
- Identified or suspected genetic syndromes.
- Autism or other pervasive developmental disorders.
- Psychiatric disorders other than ADHD and oppositional defiant disorder.
- Heart, liver or renal disease.
- Cancer.
- Epilepsy or non-febrile seizure history.
- Cardiac arrhythmia, bradycardia, or syncope.
- Any other condition considered to be potentially exacerbated or endangered by treatment with an alpha-2 agonist drug.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01146002
Start Date
June 1 2010
End Date
February 1 2013
Last Update
April 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurology Group of Bergen County
Ridgewood, New Jersey, United States, 07450